Cargando…

Characterization of Synonymous BRCA1:c.132C>T as a Pathogenic Variant

Breast cancer gene 1 (BRCA1) and BRCA2 are tumor suppressors involved in DNA damage response and repair. Carriers of germline pathogenic or likely pathogenic variants in BRCA1 or BRCA2 have significantly increased lifetime risks of breast cancer, ovarian cancer, and other cancer types; this phenomen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Jun, Wang, Ping, Zhang, Cuiyun, Han, Sile, Xiao, Han, Liu, Zhiyuan, Wang, Xiaoyan, Liu, Weiling, Wei, Bing, Ma, Jie, Li, Hongle, Guo, Yongjun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8789006/ https://www.ncbi.nlm.nih.gov/pubmed/35087763 http://dx.doi.org/10.3389/fonc.2021.812656

Ejemplares similares

Identification of BRCA1:c.5470_5477del as a Founder Mutation in Chinese Ovarian Cancer Patients
por: Li, Jun, et al.
Publicado: (2021)

Corrigendum: Identification of BRCA1:c.5470_5477del as a Founder Mutation in Chinese Ovarian Cancer Patients
por: Li, Jun, et al.
Publicado: (2022)

Efficacy and safety of treatment regimens for patients with metastatic, locally advanced, or recurrent breast cancer carrying BRCA1/BRCA2 pathogenic variants: A network meta-analysis
por: Zhu, Yingxuan, et al.
Publicado: (2023)

New Insights Into c.815_824dup Pathogenic Variant of BRCA1 in Inherited Breast Cancer: A Founder Mutation of West African Origin
por: Diop, Jean Pascal Demba, et al.
Publicado: (2022)

GEMO, a National Resource to Study Genetic Modifiers of Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Pathogenic Variant Carriers
por: Lesueur, Fabienne, et al.
Publicado: (2018)

An Ensemble Approach to Predict the Pathogenicity of Synonymous Variants
por: Ranganathan Ganakammal, Satishkumar, et al.
Publicado: (2020)

Landscape of germline BRCA1/BRCA2 variants in breast and ovarian cancer in Peru
por: Ferreyra, Yomali, et al.
Publicado: (2023)

Quantitative Analysis of BRCA1 and BRCA2 Germline Splicing Variants Using a Novel RNA-Massively Parallel Sequencing Assay
por: Farber-Katz, Suzette, et al.
Publicado: (2018)

Adolescent triple-negative breast cancer with germline pathogenic variants in both BRCA1 and TP53 genes: A case report
por: Chen, Dongmei, et al.
Publicado: (2022)

Case Report Series: Aggressive HR Deficient Colorectal Cancers Related to BRCA1 Pathogenic Germline Variants
por: Freire, Maria Valeria, et al.
Publicado: (2022)

Assessing the pathogenicity of BRCA1/2 variants of unknown significance: Relevance and challenges for breast cancer precision medicine
por: De Paolis, Elisa, et al.
Publicado: (2023)

Tumor Testing for Somatic and Germline BRCA1/BRCA2 Variants in Ovarian Cancer Patients in the Context of Strong Founder Effects
por: Peixoto, Ana, et al.
Publicado: (2020)

Prevalence and Spectrum of Germline BRCA1 and BRCA2 Variants of Uncertain Significance in Breast/Ovarian Cancer: Mysterious Signals From the Genome
por: Fanale, Daniele, et al.
Publicado: (2021)

A novel BRCA1 splicing variant detected in an early onset triple-negative breast cancer patient additionally carrying a pathogenic variant in ATM: A case report
por: Colombo, Mara, et al.
Publicado: (2023)

Case report: TP53 and RB1 loss may facilitate the transformation from lung adenocarcinoma to small cell lung cancer by expressing neuroendocrine markers
por: Li, Jun, et al.
Publicado: (2022)

Preliminary molecular evidence associating a novel BRCA1 synonymous variant with hereditary ovarian cancer syndrome
por: Minucci, Angelo, et al.
Publicado: (2018)

Corrigendum: A novel BRCA1 splicing variant detected in an early onset triple-negative breast cancer patient additionally carrying a pathogenic variant in ATM: a case report
por: Colombo, Mara, et al.
Publicado: (2023)

Erratum: Prevalence and Spectrum of Germline BRCA1 and BRCA2 Variants of Uncertain Significance in Breast/Ovarian Cancer: Mysterious Signals From the Genome
Publicado: (2022)

Decoding the effects of synonymous variants
por: Zeng, Zishuo, et al.
Publicado: (2021)

Synonymous Variants of Uncertain Silence
por: Giacoletto, Christopher J., et al.
Publicado: (2023)

Cancer Risks Associated With BRCA1 and BRCA2 Pathogenic Variants
por: Li, Shuai, et al.
Publicado: (2022)

Molecular Trajectory of BRCA1 and BRCA2 Mutations
por: Hatano, Yuichiro, et al.
Publicado: (2020)

New insights into the pathogenicity of non-synonymous variants through multi-level analysis
por: Sun, Hong, et al.
Publicado: (2019)

The BRCA2 c.68‐7T > A variant is not pathogenic: A model for clinical calibration of spliceogenicity
por: Colombo, Mara, et al.
Publicado: (2018)

Long Non-Coding RNA Neighbor of BRCA1 Gene 2: A Crucial Regulator in Cancer Biology
por: Wang, Ting, et al.
Publicado: (2021)

The pathogenic role of the BRCA2 c.7847C>T (p.Ser2616Phe) variant in breast and ovarian cancer predisposition
por: Yamazawa, Kazuki, et al.
Publicado: (2023)

BRCA1 c.4987-3C>G is a pathogenic mutation
por: Brandão, Rita D., et al.
Publicado: (2011)

Association Between Genetic Variant in the Promoter of Pri-miR-34b/c and Risk of Glioma
por: Li, Jinghui, et al.
Publicado: (2018)

BRCA Variants Do Not Increase the Risk of Adverse Reactions in Patients With Ovarian Cancer: A Single-Center Real-World Study
por: Li, Kemin, et al.
Publicado: (2022)

Assessment of the Prognostic Value of Two Common Variants of BRCA1 and BRCA2 Genes in Ovarian Cancer Patients Treated with Cisplatin and Paclitaxel: A Gynecologic Oncology Group Study
por: Tian, Chunqiao Q., et al.
Publicado: (2013)

Expansion of Cancer Risk Profile for BRCA1 and BRCA2 Pathogenic Variants
por: Momozawa, Yukihide, et al.
Publicado: (2022)

When a Synonymous Variant Is Nonsynonymous
por: Vihinen, Mauno
Publicado: (2022)

BRCA 1/BRCA 2 Pathogenic/Likely Pathogenic Variant Patients with Breast, Ovarian, and Other Cancers
por: Osman, K., et al.
Publicado: (2023)

Platinum-Based Neoadjuvant Chemotherapy for Breast Cancer With BRCA Mutations: A Meta-Analysis
por: Wang, Chang-Jun, et al.
Publicado: (2020)

The Oncogenic Role of APC/C Activator Protein Cdc20 by an Integrated Pan-Cancer Analysis in Human Tumors
por: Wu, Fei, et al.
Publicado: (2021)

Multifactorial Likelihood Assessment of BRCA1 and BRCA2 Missense Variants Confirms That BRCA1:c.122A>G(p.His41Arg) Is a Pathogenic Mutation
por: Whiley, Phillip J., et al.
Publicado: (2014)

Somatic IDH1 variant (p.R132C) in an adult male with Maffucci syndrome
por: Brown, Natasha J., et al.
Publicado: (2021)

Analysis of BRCA Germline Mutations in Chinese Prostate Cancer Patients
por: Chen, Wei, et al.
Publicado: (2022)

BRCA1 Versus BRCA2 and PARP Inhibitors Efficacy in Solid Tumors:A Meta-Analysis of Randomized Controlled Trials
por: Li, Shan, et al.
Publicado: (2021)

Genomic Profiling Comparison of Germline BRCA and Non-BRCA Carriers Reveals CCNE1 Amplification as a Risk Factor for Non-BRCA Carriers in Patients With Triple-Negative Breast Cancer
por: Huang, Xin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_0d1v0ogfe9v3vqtmftit4afbpd